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OBJECTIVES: To determine the cost of Dupuytren=s contracture in the Czech
Republic. METHODS: Survey among general surgery specialists and orthopedic
surgeons (panel of total 9 surgeons) conducted. The assessment itself was done
using a classical Delphi panel method, combined with data from medical charts
and/or hospital information systems. Besides the surgeons, also rehabilitation spe-
cialists (to cover costs for rehabilitation) and internal medicine specialists (to cover
complications) were included into the panel. RESULTS: If indirect costs (productiv-
ity loss) are included, they represent the major part of all costs (76 %). In case of
direct cost inclusion, rehabilitation stands for more than 50% of costs, followed by
surgery costs (almost 30 %). Mean direct costs (1 operation field) are estimated at
about 12,000 CZK with a variation of 9 200 to 14,400 CZK. If indirect costs (produc-
tivity loss) are included, total costs increase dramatically, arriving at mean costs of
almost 50 thousand CZK (21,800 to 90,200 CZK). CONCLUSIONS: Cost of Dupuyt-
ren=s contracture range from 21,800 to 90 200 CZK if indirect cost included. Indirect
cost represent 76% of all costs.
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OBJECTIVES: To evaluate utilization of resources and direct medical costs of post-
menopausal osteoporosis treatment in patients without fractures. METHODS: A
medical chart review was performed to examine the medical resources used to
treat osteoporosis during the year preceding the start of the study. Data were
collected between July 2010 and April 2011 by local investigators from 5 centers in
Slovenia (99 patients), 5 in Serbia (105), 10 in Slovakia (100) and 3 in Bulgaria (106).
Data of patients above 50 years of age, diagnosed with osteoporosis without frac-
tures and treated for osteoporosis was included in the study. Based on these data,
costs of osteoporosis treatment from the public payer and patient’s perspective in
all countries except Bulgaria were estimated. Costs of ambulatory and outpatient
visits, examinations and drugs were calculated. RESULTS: Patients with osteopo-
rosis were monitored more frequently in Slovenia and Slovakia (on average 2.00
and 1.87 ambulatory visits per year, respectively). In Serbia and Bulgaria, ambula-
tory visits were less frequent (0.79 and 0.67 visits per year, respectively). Percent-
ages of patients treated with bisphosphonates were 99%, 98%, 78% and 61% in
Slovakia, Bulgaria, Slovenia and Serbia, respectively, while 83%, 85%, 81% and 57%
was treated with calcium and vitamin D supplements, respectively. Average 1-year
cost of osteoporosis treatment was highest in Slovakia and Slovenia, accounting for
491 € (CI95%: 444; 634) and 384 € (CI95%: 345; 435), respectively, while in Serbia these
costs were 190 € (CI95%: 164; 231). CONCLUSIONS: The highest standard of treat-
ment and monitoring osteoporosis was observed in Slovenia. On the other side
treatment of osteoporotic patients generated the highest costs in Slovakia, how-
ever some of these costs could be related to comorbidities.
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OBJECTIVES: To evaluate utilization of resources and direct medical costs of post-
menopausal osteoporotic fractures (proximal femur and vertebral) in the first and
subsequent years after the event. METHODS: A medical chart review was per-
formed to examine the medical resources used to treat the two most costly osteo-
porotic fractures in the first and second or subsequent year after the event. Data
were collected between December 2009 and April 2011 by local investigators from 5
centers in Slovenia (159 patients), 5 in Serbia (199) and 3 in Bulgaria (186). Docu-
mentation of patients above 50 years of age with a low-energy fracture sustained
no later than 5 years before the start of the study was included. Patients with
multiple fractures were excluded. Cost of treatment from a public payer and pa-
tient perspective in all countries except Bulgaria was estimated. These costs were
compared to GDP per capita in each country (International Monetary Fund data –
year 2010: 15,953 € in Slovenia, 3,522 € in Serbia) to evaluate economic burden of
fractures. RESULTS: All Slovenian patients were hospitalized after proximal femur
and 53% after vertebral fracture, compared with 84% and 30% in Serbia and 69% and
5% in Bulgaria. However, in the following years after the fracture, hospitalization
was most common in Serbia (49% of patients after proximal femur and 18% after
vertebral fracture yearly).The 2-year treatment cost of proximal femur fracture was
4463 € (SD 1750) in Slovenia and 3277 € (SD 2409) in Serbia, while the 2-year cost of
vertebral fracture during was estimated at 3902 € (SD 2714) in Slovenia and 491 € (SD
295) in Serbia. CONCLUSIONS: Osteoporotic fractures are responsible for high eco-
nomic burden. Mean cost of treatment of low-energy proximal femur fracture is
equal 28% of GDP per capita in Slovenia and 93% in Serbia.
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OBJECTIVES: In the 1-year, double-blind, placebo-controlled ATTEST trial, efficacy
of abatacept or infliximab vs. placebo was reported in patients with rheumatoid
arthritis (RA) and inadequate response to methotrexate. We estimated trial-based
and real life costs of abatacept and infliximab for achieving pre-defined remission
or low disease activity state (LDAS) as recommended by the European League
Against Rheumatism (EULAR). METHODS: Quantity of drug, serious adverse event
(SAE) rates and time (months) in remission or LDAS were taken from ATTEST for
the trial-based calculation to derive a cost per remitting/LDAS patient and cost per
patient-month in remission/LDAS. We used list prices for drugs and public tariffs
for infusion and hospitalization due to SAEs. Trial-based analyses were made for
the full year, and the first and subsequent 6 months (initiation & maintenance).
Maintenance costs were extrapolated to real life, taking into account dose escala-
tion and shortening of infusion intervals with infliximab. SAE rates from a Co-
chrane network meta-analysis were considered in the real-life analyses. All anal-
yses were conducted from a health care system perspective for Italy. RESULTS: In
Italy, the annual trial-based costs per remitting/LDAS patient were €70,259/€37,219
for abatacept vs. €85,547/€46,592 for infliximab. In the initiation phase, costs per
patient-month in remission/LDAS were €11,028/€6,020 for abatacept vs. €8,347/
€4,173 for infliximab. Abatacept showed lower costs per patient-month in remis-
sion/LDAS in the maintenance phase €5,046/€2,673 vs. €5,500/€2,996 for infliximab.
Real-life maintenance costs per month in remission/LDAS were: €5,347/€2,832 for
abatacept vs. €7,210/€3,927 for infliximab. Higher initiation cost for abatacept to
achieve remission/LDAS would be offset at 14.6/16.1 months during real life.
CONCLUSIONS: Our findings suggest a lower cost-consequence for abatacept dur-
ing the maintenance phase and its real-life extrapolation. Abatacept is a sustain-
able, safe, and economically attractive biologic for the long-term treatment of RA
when compared to infliximab.
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OBJECTIVES: To evaluate the cost-effectiveness of treatment sequences initialized
with tocilizumab 8mg/kg compared to similar treatment sequences initialized with
a TNF-inhibitor for the treatment of moderate to severe RA patients with inade-
quate response to previous DMARD therapy (DMARD-IR) in Portugal. METHODS: A
cost-utility analysis was conducted from a societal perspective. The analysis com-
pares DMARD-IR patient outcomes, in three different scenarios, in a treatment
sequence initialized with tocilizumab followed by a TNF inhibitor (adalimumab,
etanercept, or infliximab, for scenarios 1, 2 and 3, respectively), rituximab, abata-
cept and palliation versus the same sequence initialized with a TNF inhibitor (et-
anercept, adalimumab and etanercept, respectively, for scenarios 1, 2 and 3). Pa-
tients characteristics (age, starting HAQ-DI score, sex and weight) were based on
tocilizumab clinical trial data. ACR response for biologic treatments was obtained
by a mixed treatment comparison. Clinical trial data was used to model the rela-
tionship between HAQ-DI scores and utility as described by EQ-5D. Resource utili-
zation was obtained from an expert panel of Portuguese rheumatologists. Unit
costs were obtained from Portuguese official sources. Analysis of clinical trial data
or secondary sources provided evidence for appropriate distributions to perform
probabilistic sensitivity analysis (PSA). Costs and QALYs were discounted annually
at 5%. RESULTS: The model estimated that the treatment sequence initialized with
tocilizumab resulted in higher QALYs and lower costs versus comparator se-
quences in all three scenarios (0.22 QALYs and1.881€, 0.27 QALYs and4.449€, 0.22
QALYs and 1.851€ for scenarios 1, 2 and 3 respectively). Several sensitivity and sce-
narios analyses showed that the model is robust to changes in parameter values. In
PSA (2000 samples) the tocilizumab sequence produces always additional QALYs at
lower costs.CONCLUSIONS: In DMARD-IR patients, the model consistently predicts
that starting treatment with tocilizumab is a dominant alternative compared to
similar treatment sequences initialized with a TNF-inhibitor in Portugal.
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